Polyarticular Juvenile Idiopathic Arthritis Drug Market Report

Global and Region Polyarticular Juvenile Idiopathic Arthritis Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：225
  • REPORT CODE：GMM932410
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Polyarticular Juvenile Idiopathic Arthritis Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Polyarticular Juvenile Idiopathic Arthritis Drugmarket, defines the market attractiveness level of Polyarticular Juvenile Idiopathic Arthritis Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Polyarticular Juvenile Idiopathic Arthritis Drug industry, describes the types of Polyarticular Juvenile Idiopathic Arthritis Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Polyarticular Juvenile Idiopathic Arthritis Drug market and the development prospects and opportunities of Polyarticular Juvenile Idiopathic Arthritis Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Polyarticular Juvenile Idiopathic Arthritis Drug market in Chapter 13.

    By Player:

    • UCB SA

    • Regeneron Pharmaceuticals Inc

    • Livzon Pharmaceutical Group Inc

    • Coherus BioSciences Inc

    • Oncobiologics Inc

    • Sandoz International GmbH

    • Oncodesign SA

    • Momenta Pharmaceuticals Inc

    • Panacea Biotec Ltd

    • Biocon Ltd

    • Mycenax Biotech Inc

    By Type:

    • Etanercept Biosimilar

    • Tocilizumab Biosimilar

    • Sarilumab

    • Adalimumab Biosimilar

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Polyarticular Juvenile Idiopathic Arthritis Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Polyarticular Juvenile Idiopathic Arthritis Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Polyarticular Juvenile Idiopathic Arthritis Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Polyarticular Juvenile Idiopathic Arthritis Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Polyarticular Juvenile Idiopathic Arthritis Drug Market Analysis and Outlook to 2022

    • 7.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.2 United States Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.4 China Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.5 Japan Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.6 India Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    • 7.7 South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Consumption (2017-2022)

    8 Region and Country-wise Polyarticular Juvenile Idiopathic Arthritis Drug Market Analysis and Outlook to 2028

    • 8.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.2 United States Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.4 China Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.6 India Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast (2022-2028)

    9 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Etanercept Biosimilar Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Tocilizumab Biosimilar Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Sarilumab Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Adalimumab Biosimilar Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Etanercept Biosimilar Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Tocilizumab Biosimilar Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Sarilumab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Adalimumab Biosimilar Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Polyarticular Juvenile Idiopathic Arthritis Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Polyarticular Juvenile Idiopathic Arthritis Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Competitive Analysis

    • 14.1 UCB SA

      • 14.1.1 UCB SA Company Details

      • 14.1.2 UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.2 Regeneron Pharmaceuticals Inc

      • 14.2.1 Regeneron Pharmaceuticals Inc Company Details

      • 14.2.2 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.3 Livzon Pharmaceutical Group Inc

      • 14.3.1 Livzon Pharmaceutical Group Inc Company Details

      • 14.3.2 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.4 Coherus BioSciences Inc

      • 14.4.1 Coherus BioSciences Inc Company Details

      • 14.4.2 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.5 Oncobiologics Inc

      • 14.5.1 Oncobiologics Inc Company Details

      • 14.5.2 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.6 Sandoz International GmbH

      • 14.6.1 Sandoz International GmbH Company Details

      • 14.6.2 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.7 Oncodesign SA

      • 14.7.1 Oncodesign SA Company Details

      • 14.7.2 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.8 Momenta Pharmaceuticals Inc

      • 14.8.1 Momenta Pharmaceuticals Inc Company Details

      • 14.8.2 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.9 Panacea Biotec Ltd

      • 14.9.1 Panacea Biotec Ltd Company Details

      • 14.9.2 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.10 Biocon Ltd

      • 14.10.1 Biocon Ltd Company Details

      • 14.10.2 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • 14.11 Mycenax Biotech Inc

      • 14.11.1 Mycenax Biotech Inc Company Details

      • 14.11.2 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Polyarticular Juvenile Idiopathic Arthritis Drug

    • Figure Polyarticular Juvenile Idiopathic Arthritis Drug Picture

    • Table Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Polyarticular Juvenile Idiopathic Arthritis Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption by Country (2017-2022)

    • Figure United States Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Figure China Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Figure India Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Etanercept Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Global Tocilizumab Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Global Sarilumab Consumption and Growth Rate (2017-2022)

    • Figure Global Adalimumab Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Etanercept Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tocilizumab Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sarilumab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adalimumab Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Polyarticular Juvenile Idiopathic Arthritis Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Polyarticular Juvenile Idiopathic Arthritis Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table UCB SA (Foundation Year, Company Profile and etc.)

    • Table UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Regeneron Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Livzon Pharmaceutical Group Inc (Foundation Year, Company Profile and etc.)

    • Table Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Coherus BioSciences Inc (Foundation Year, Company Profile and etc.)

    • Table Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Oncobiologics Inc (Foundation Year, Company Profile and etc.)

    • Table Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Sandoz International GmbH (Foundation Year, Company Profile and etc.)

    • Table Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Oncodesign SA (Foundation Year, Company Profile and etc.)

    • Table Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Momenta Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Panacea Biotec Ltd (Foundation Year, Company Profile and etc.)

    • Table Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Biocon Ltd (Foundation Year, Company Profile and etc.)

    • Table Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service

    • Table Mycenax Biotech Inc (Foundation Year, Company Profile and etc.)

    • Table Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US